Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
lundi, octobre 19
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Globus Medical Inc
GMED
NYSE
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$76.71
-2.13
-2.7%
Dern. MÀJ: Oct 16, 4:00 PM
$76.71
-2.13
-2.7%
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Privacy Manager
Globus Medical Financials
Globus Medical (GMED) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Globus Medical Raises FY2026 Adj EPS Guidance from $4.70-$4.80 to $4.95-$5.05 vs $4.74 Est; Affirms FY2026 Sales Guidance of $3.180B-$3.220B vs $3.201B Est
Globus Medical (NYSE:GMED) raises FY2026 Adj EPS guidance from $4.70-$4.80 to $4.95-$5.05 vs $4.74 analyst estimate. Affirms FY2026 sales outlook from $3.180 billion-$3.220 billion to $3.180 billion-$3.220 billion vs
Benzinga Newsdesk
PRO
Globus Medical Q2 Adj. EPS $1.34 Beats $1.10 Estimate, Sales $789.612M Beat $782.840M Estimate
Globus Medical (NYSE:GMED) reported quarterly earnings of $1.34 per share which beat the analyst consensus estimate of $1.10 by 21.82 percent. This is a 55.81 percent increase over earnings of $0.86 per share from the
Benzinga Newsdesk
PRO
Globus Medical Raises FY2026 Adj EPS Guidance from $4.40-$4.50 to $4.70-$4.80 vs $4.47 Est; Affirms FY2026 Sales Guidance of $3.180B-$3.220B vs $3.202B Est
Globus Medical (NYSE:GMED) raises FY2026 Adj EPS guidance from $4.40-$4.50 to $4.70-$4.80 vs $4.47 analyst estimate. Affirms FY2026 sales outlook from $3.180 billion-$3.220 billion to $3.180 billion-$3.220 billion vs
Benzinga Newsdesk
PRO
Globus Medical Q1 Adj. EPS $1.12 Beats $0.92 Estimate, Sales $759.854M Beat $736.999M Estimate
Globus Medical (NYSE:GMED) reported quarterly earnings of $1.12 per share which beat the analyst consensus estimate of $0.92 by 21.74 percent. This is a 64.71 percent increase over earnings of $0.68 per share from the
Benzinga Newsdesk
PRO
Globus Medical Raises FY2026 Adj EPS Guidance from $4.30-$4.40 to $4.40-$4.50 vs $4.26 Est; Affirms FY2026 Sales Guidance of $3.180B-$3.220B vs $3.165B Est
Benzinga Newsdesk
PRO
Globus Medical Q4 Adj. EPS $1.28 Beats $1.15 Estimate, Sales $826.420M Beat $799.123M Estimate
Benzinga Newsdesk
